Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.

Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.

Cancer Treat Res Commun. 2019;19:100121. doi: 10.1016/j.ctarc.2019.100121. Epub 2019 Feb 6.

2.
3.

Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.

Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guérin A.

Adv Ther. 2016 Jun;33(6):983-97. doi: 10.1007/s12325-016-0328-3. Epub 2016 May 23.

PMID:
27216253
4.
5.

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.

Osborne C, Challagalla JD, Eisenbeis CF, Holmes FA, Neubauer MA, Koutrelakos NW, Taboada CA, Vukelja SJ, Wilks ST, Allison MA, Reddy P, Sedlacek S, Wang Y, Asmar L, O'Shaughnessy J.

Clin Breast Cancer. 2018 Feb;18(1):e89-e95. doi: 10.1016/j.clbc.2017.07.002. Epub 2017 Jul 10.

6.

Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.

Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L.

Curr Med Res Opin. 2012 Mar;28(3):419-28. doi: 10.1185/03007995.2011.628649. Epub 2012 Feb 24.

PMID:
22364568
7.

Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.

Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ.

Exp Hematol Oncol. 2015 Dec 12;4:31. doi: 10.1186/s40164-015-0023-0. eCollection 2015.

8.
9.

Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.

Gauthier G, Gagnon-Sanschagrin P, Guérin A, Burne R, Small T, Niravath P, Dalal AA.

Adv Ther. 2018 Apr;35(4):503-514. doi: 10.1007/s12325-018-0689-x. Epub 2018 Mar 20.

PMID:
29556908
10.

First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.

Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS.

Oncologist. 2013;18(5):501-10. doi: 10.1634/theoncologist.2012-0414. Epub 2013 May 7.

11.

Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review.

Parisi M, Pelletier C, Cherepanov D, Broder MS.

J Comp Eff Res. 2018 Jan;7(1):67-83. doi: 10.2217/cer-2017-0027. Epub 2018 Jan 5.

13.

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G.

Cancer Manag Res. 2018 May 4;10:1015-1025. doi: 10.2147/CMAR.S162714. eCollection 2018.

14.

A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.

Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z.

Cancer Biol Ther. 2015;16(2):225-32. doi: 10.4161/15384047.2014.986973.

15.

Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.

Schroeder MC, Rastogi P, Geyer CE Jr, Miller LD, Thomas A.

Oncologist. 2018 Apr;23(4):481-488. doi: 10.1634/theoncologist.2017-0398. Epub 2018 Jan 12.

16.

Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.

Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM, Flanders SC, Barlev A, Fryzek JP, Quek RGW.

Cancer. 2018 May 15;124(10):2104-2114. doi: 10.1002/cncr.31299. Epub 2018 Mar 5.

PMID:
29505670
17.

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.

Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH.

Int J Cancer. 2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090.

18.

Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.

Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA.

Curr Med Res Opin. 2015 Jun;31(6):1095-103. doi: 10.1185/03007995.2015.1021906. Epub 2015 May 13. Erratum in: Curr Med Res Opin. 2019 May;35(5):937.

PMID:
25971725
19.

Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, Press MF, Gagnon R, Ellis C, Johnston S.

JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922.

PMID:
27281556
20.

Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.

Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ.

J Natl Compr Canc Netw. 2014 Jan;12(1):71-80.

PMID:
24453294

Supplemental Content

Support Center